ar			
Notice of Allowability	Application No.	Applicant(s)	
	10/667,494	LEUNG ET AL.	
	Examiner	Art Unit	
	David J. Steadman	1656	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <u>amendments filed 10 March 2005 and 15 June 2005</u> .			
2. The allowed claim(s) is/are 1.			
3. X The drawings filed on 10 March 2005 and 23 September 2003 are accepted by the Examiner.			
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of			
each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s)	E Mating of Information	otant Application (DT)	152)
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 	5. ☐ Notice of Informal P.6. ☐ Interview Summary	• • • • • • • • • • • • • • • • • • • •	J-102 <i>j</i>
	Paper No./Mail Date		
Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date	· ·		
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	nt of Reasons for Allo	wance
of Biological Material	9. Other		
		**	

Application/Control Number: 10/667,494

Art Unit: 1656

DETAILED ACTION

Status of the Application

- [1] The Art Unit location of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1656.
- [2] Claim 1 is pending in the application.
- [3] Applicants' amendment to claim 1, filed 3/10/2005, is acknowledged. This claim listing replaces all prior versions and listings of the claims.
- [4] Applicants' amendment to the specification, filed 6/15/2005, is acknowledged. This amendment perfects a previous amendment filed 3/10/2005, which fails to satisfy the requirements of 37 CFR 1.121 for reasons set forth in the Office communication mailed 6/2/2005.
- [5] Applicants' amendment to the drawing figures, filed 3/10/2005, is acknowledged.

Reasons for Allowance

The following is an Examiner's statement of reasons for allowance. The examiner has found no teaching or suggestion in the prior art directed to the polypeptide of SEQ ID NO:13. Therefore, claim 1, drawn to an isolated polypeptide having lysophosphatidic acid acyltransferase activity and comprising SEQ ID NO:13, is allowable over the prior art of record.

The specification discloses (p. 1) LPAAT polypeptides catalyze the production of phosphatidic acid (PA). The polypeptide of SEQ ID NO:13 was shown to have LPAAT

Application/Control Number: 10/667,494

Art Unit: 1656

activity by virtue of its ability to produce PA (Figure 13). The instant specification and the prior art (e.g., US Patents 5,470,878 and 5,288,721) acknowledge that compounds that block the production of PA by inhibiting LPAAT activity are useful for, e.g., reducing inflammation. The specification asserts the claimed polypeptide is useful for screening compounds that inhibit LPAAT activity, which, in view of the teachings of the specification and prior art, is a specific and substantial asserted utility.

[7] Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Steadman whose telephone number is 571-272-0942. The examiner can normally be reached on Monday to Thursday and alternate Fridays, 7:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr can be reached on 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dávid J. Šteadman, Ph.D. Primary Examiner Art Unit 1656